Reducing Chemoradiotherapy And Radiation With Targeted Immunotherapy in Children, Adolescents and Young Adults With Lymphoma

Reducing Chemoradiotherapy And Radiation With Targeted Immunotherapy in Children, Adolescents and Young Adults With Lymphoma
Conditions:   Non-hodgkin Lymphoma;   Hodgkin Lymphoma
Interventions:   Drug: DOC Group B;   Drug: COMRAD 1 and 2 Group B;   Drug: R-CYM 1 and 2 Group B;   Drug: DOC Group C;   Drug: MAD CPR 1 and 2;   Drug: Pv-R CYVE 1 and 2;   Drug: Pv-R CYVE-MTX 1 and 2;   Drug: MAD CP;   Drug: Pv-Cytarabine/etoposide;   Drug: AD CP;   Drug: Bv-AVD-R 1 and 2: COHORT IIa;   Drug: Bv-NVD-R, Cycle 1-2;   Drug: Bv-NVD-R, Cycle 1-4;   Drug: Bv-AVD-R;   Drug: Bv-NAVD-R, Cycle 1-2;   Radiation: Involved Site Radiation Therapy
Sponsor:   New York Medical College
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 24, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments